<DOC>
	<DOCNO>NCT01043120</DOCNO>
	<brief_summary>The main purpose clinical research trial evaluate effect barusiban compare placebo uterine contraction luteal phase uterine contraction oocyte donor supplement progesterone .</brief_summary>
	<brief_title>Effect Oxytocin Antagonist Reduction Uterine Contractions</brief_title>
	<detailed_description>This randomise , double-blind , parallel group , placebo-controlled , multi-centre trial . It design evaluate efficacy barusiban , selective oxytocin antagonist , reduce frequency uterine contraction day embryo transfer . Participants trial oocyte donor undergo control ovarian hyperstimulation long gonadotrophin-releasing hormone ( GnRH ) agonist protocol multiple-dose GnRH antagonist protocol , receive human chorionic gonadotrophin ( hCG ) trigger final follicular maturation undergone oocyte retrieval ( OR ) yield ≥ 6 cumulus-oocyte-complexes . The duration trial two day : Day OR +2 ( screen , randomisation dose investigational medicinal product ) Day OR +3 ( end-of-trial ) . On Day OR +2 , participant screen subsequently randomise barusiban placebo . All participant receive intravenous ( IV ) bolus 1 minute follow IV infusion 59 minute , administer via indwell catheter , barusiban placebo . Bolus volume infusion rate identical barusiban placebo . A mock embryo transfer ( MET ) procedure perform 40 minute start dose include intrauterine administration non-radioactive ultrasound contrast agent ( SONOVUE ) via embryo transfer catheter . Transvaginal ultrasound around 5 minute duration perform seven time point Day OR +2 cover span approximately 2.5 hour include pre-dosing , dosing , mock embryo transfer , post-dosing . The transvaginal ultrasound recording analyse frequency uterine contraction uterine contractility parameter central independent assessor , blind treatment allocation . Movement ultrasound contrast agent mock embryo transfer procedure evaluate central independent assessor . As attempt document impact uterine contraction potential embryo expulsion , exploratory evaluation movement ultrasound contrast agent ( SONOVUE ) administer intrauterinely via embryo transfer catheter mock embryo transfer perform . The anatomical point release ultrasound contrast agent ( correct incorrect deposition site , estimate distance fundus ) well immediate movement ( yes/no ) bolus record central independent assessor . Definitions : The frequency uterine contraction define number uterine contraction per minute . A contraction define one sequential upward downward vertical displacement endometrial / myometrial interface time . The frequency inverse period convert contraction per minute . The period average time take complete one contraction study time interval . It calculate peak trough anterior posterior endometrial /myometrial interface . The period measure second per contraction . The external contractile measure mean wave amplitude mm lumenal surface . This metric measure lumenal peak troughs measurement design study relationship endometrial wave activity , manifest bulk motion uterus , versus internal contractile strength . The external contractile measure report mm/contraction . The external contractile measure quantify movement uterus whole measure lumen , i.e . motion uterus relative body . The internal contractile measure strength contraction base upon sum contraction amplitude measure anterior posterior endometrial / myometrial interface . The amplitude interface define average difference endometrial / myometrial-lumenal distance measure peak troughs endometrial / myometrial interface . The internal contractile measure report mm/contraction . The internal contractile measure quantify movement endometrium relative lumen , i.e . motion internal uterus . The total contractile measure sum external contractile measure internal contractile measure quantify total muscle movement uterus . If wave anterior posterior endometrial / myometrial interface phase endometrial motion relative lumen motion pure wave motion internal contractile measure equal zero . The total contractile measure report mm/contraction . Inter-subendometrial space measure clinically distance anterior stratum basalis posterior stratum basalis layer mid-sagittal plane anatomic location 5 10 mm fundus . All clinical inter-subendometrial space measurement make select clear image uterus , wait contraction pas freeze image . A linear distance measurement take anatomic landmark describe . Inter-subendometrial space calculate exist measurement use mean measurement identify endometrial-myometrial interface superior inferior surface endometrial strip arrows identify endometrial contraction place motion analysis . Inter-subendometrial space report mm . The direction wave propagation classify one following : - Fundal ( cervix fundus ) - Cervical ( fundus cervix ) - Convergent ( oppose ) start simultaneously cervix fundus - Focal local contraction ( involve whole uterine wall ) - No activity - NE : evaluable At assessment time point , predominant type direction wave propagation record . Dispersion ultrasound contrast agent bolus release catheter record yes/no number disperse fragment , applicable . Location ultrasound contrast agent bolus categorise follow : - Upper 1/3 ( fundal ) part uterine cavity - Central 1/3 uterine cavity - Lower 1/3 ( cervical ) part uterine cavity - Intralumenal part Fallopian tube - Intra-cervical - Vaginal - NE : evaluable Distance apex fundus myometrial-endometrial interface position microdroplet ultrasound contrast agent record mm . Velocity bolus ultrasound contrast agent assess distance time , record mm/hour .</detailed_description>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Participants eligible trial oocyte donor 1837 year age , undergone control ovarian hyperstimulation long GnRH agonist protocol multipledose singledose GnRH antagonist protocol , receive hCG ( 10,000 IU urinary hCG 250 μg recombinant hCG ) trigger final follicular maturation undergone oocyte retrieval . Participants give sign informed consent , generally healthy body mass index ( BMI ) 18.529 kg/m2 . Participants exclude case endometriosis stage IIV uterine pathology . Participants willing intake alcoholic beverage trial , sexual intercourse trial , either maintain sexual abstinence use highly effective method contraception endoftrial till onset next menses .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>